Cerenome Secures National In-Network Agreement With Aetna for CNSide

Cerenome says it now contracts with approximately 85% of private payers in the US, representing approximately 190 million covered lives. The Aetna agreement is its first national CNSide payer agreement to include tumor cell enumeration and molecular profiling.